Search

Your search keyword '"Novartis Pharma AG -- Licensing agreements"' showing total 122 results
Start Over Descriptor "Novartis Pharma AG -- Licensing agreements"
122 results on '"Novartis Pharma AG -- Licensing agreements"'

1. Legend Biotech Closes License Transaction for Certain CAR-T Therapies Targeting DLL3

Subjects
Novartis Pharma AG -- Licensing agreements, T cells, Biotechnology, Company licensing agreement, Arts and entertainment industries
Abstract

Legend Biotech Corp. closed its previously reported exclusive, worldwide license agreement with Novartis Pharma AG (Novartis) for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand [...]

Published
2024

2. Legend Biotech Closes License Transaction for Certain CAR-T Therapies Targeting DLL3

Subjects
Novartis Pharma AG -- Licensing agreements, T cells, Biotechnology, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Arts and entertainment industries
Abstract

Legend Biotech Corp. closed its previously reported exclusive, worldwide license agreement with Novartis Pharma AG (Novartis) for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand [...]

Published
2024

3. Voyager inks capsid license agreement and strategic collaboration with Novartis to advance novel gene therapies

Subjects
Novartis Pharma AG -- Licensing agreements, Intellectual property, Genes, Gene therapy, Tracers (Biology), Intellectual property, Company licensing agreement, Pharmaceuticals and cosmetics industries
Abstract

Voyager Therapeutics, Inc., a biotechnology company dedicated to advancing neurogenetic medicines, announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG to advance [...]

Published
2024

4. Monte Rosa licenses VAV1 degrader to Novartis

Subjects
Novartis Pharma AG -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business
Abstract

M2 EQUITYBITES-October 28, 2024-Monte Rosa licenses VAV1 degrader to Novartis (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Monte Rosa Therapeutics Inc (Nasdaq:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, [...]

Published
2024

5. Monte Rosa licenses VAV1 degrader to Novartis

Subjects
Novartis Pharma AG -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-October 28, 2024-Monte Rosa licenses VAV1 degrader to Novartis (C)2024 M2 COMMUNICATIONS Monte Rosa Therapeutics Inc (Nasdaq:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, announced [...]

Published
2024

6. MPP inks agreement for generic version of Novartis cancer drug

Subjects
Novartis Pharma AG -- Licensing agreements, Nilotinib, Antineoplastic agents -- Licensing agreements, Generic drugs -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Antimitotic agents -- Licensing agreements, Company licensing agreement, News, opinion and commentary
Abstract

June 23 -- In a move that would improve access and affordability, the Medicines Patent Pool (MPP) has signed sublicence agreements with four companies, including three from India, to manufacture [...]

Published
2023

7. Cipla, Novartis AG ink agreement on diabetes therapy Galvus

Subjects
Novartis Pharma AG -- Licensing agreements, Diabetes therapy -- Licensing agreements, Company licensing agreement, News, opinion and commentary
Abstract

April 11 -- Drugmaker Cipla has formalised an agreement with Novartis Pharma AG that will allow it to make and market diabetes therapy Galvus and its combination brands from January [...]

Published
2023

8. Legend Biotech Announced Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3

Subjects
Novartis Pharma AG -- Licensing agreements, T cells, Biotechnology, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

SOMERSET: Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, closed its previously announced exclusive, worldwide license agreement [...]

Published
2024

9. Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3

Subjects
Novartis Pharma AG -- Licensing agreements, T cells, Biotechnology, Company licensing agreement, Business, Business, international
Abstract

SOMERSET, N.J. -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, closed its previously announced exclusive, worldwide [...]

Published
2024

10. Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies

Subjects
Novartis Pharma AG -- Licensing agreements, Genes, Gene therapy, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

- Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington's disease and spinal muscular atrophy - - Voyager to receive up-front consideration of $100 [...]

Published
2024

11. To Promote Novel Gene Therapies, Voyager Therapeutics and Novartis Enter a Capsid License Agreement and Strategic Collaboration

Subjects
Novartis Pharma AG -- Licensing agreements, Genes, Gene therapy, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG [...]

Published
2024

12. Voyager inks accord with Novartis to advance novel gene therapies

Subjects
Novartis Pharma AG -- Licensing agreements, Genes, Gene therapy, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

LEXINGTON: Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of [...]

Published
2024

13. Legend Biotech announces license agreement for certain CAR-T therapies targeting DLL3

Subjects
Novartis Pharma AG -- Licensing agreements, T cells, Biotechnology, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

SOMERSET: Legend Biotech Corporation (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced that Legend Biotech Ireland Limited, a wholly owned subsidiary [...]

Published
2023

14. Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3

Subjects
United States. Food and Drug Administration, Novartis Pharma AG -- Licensing agreements, T cells, Biotechnology, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, Business, international
Abstract

* The deal with Novartis seeks to advance Legend Biotech's autologous CAR-T cell therapy candidate, LB2102, and other potential CAR-T cell therapies targeting Delta-like ligand protein 3 (DLL3), using the [...]

Published
2023

15. Legend Biotech Closes License Transaction for Certain CAR-T Therapies Targeting DLL3

Subjects
Novartis Pharma AG -- Licensing agreements, T cells, Biotechnology, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, Business, international, Telecommunications industry
Abstract

Legend Biotech Corp. closed its previously reported exclusive, worldwide license agreement with Novartis Pharma AG (Novartis) for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand [...]

Published
2024

16. Legend Biotech Closes License Transaction for Certain CAR-T Therapies Targeting DLL3

Subjects
Novartis Pharma AG -- Licensing agreements, T cells, Biotechnology, Company licensing agreement, Business, Business, international, Telecommunications industry
Abstract

Legend Biotech Corp. closed its previously reported exclusive, worldwide license agreement with Novartis Pharma AG (Novartis) for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand [...]

Published
2024

17. Cipla signs perpetual license agreement with Novartis for GalvusaA

Subjects
Novartis Pharma AG -- Licensing agreements, Diabetes therapy -- Licensing agreements, Hypoglycemic agents, Type 2 diabetes, Company licensing agreement, News, opinion and commentary
Abstract

Cipla has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) on 10 April 2023 to manufacture and market Galvusaà and Galvusaà combination brands, used in the treatment of [...]

Published
2023

18. Cipla and Novartis signed a perpetual licence for Galvus diabetes therapy in India

Subjects
Novartis Pharma AG -- Licensing agreements, Cipla Ltd. -- Licensing agreements, Diabetes therapy -- Licensing agreements, Hypoglycemic agents, Type 2 diabetes, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that Cipla Limited has signed a perpetual license agreement with Novartis Pharma AG [...]

Published
2023

19. Cipla inks agreement with Novartis Pharma AG

Subjects
Novartis Pharma AG -- Licensing agreements, Diabetes therapy -- Licensing agreements, Type 2 diabetes, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

This deal is expected to further bolster Cipla's position in India as one of the top players in the diabetes category Cipla has signed a perpetual license agreement with Novartis [...]

Published
2023

20. Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease

Subjects
Novartis Pharma AG -- Licensing agreements, Sickle cell anemia, Genes, Biotechnology industry -- Licensing agreements, Industrial research -- Switzerland, Pharmaceutical industry -- Licensing agreements, Research and development, Company licensing agreement, General interest, News, opinion and commentary
Abstract

DURHAM: PRECISION BIOSCIENCES, INC. has issued the following news release: Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in [...]

Published
2022

21. Mintz Advises BeiGene in Expanded Collaboration with Novartis to Develop and Commercialize BeiGene's TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China

Subjects
Novartis Pharma AG -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Boston, Massachusetts: Mintz has issued the following press release: Mintz advised biotechnology company BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) in its recently announced option, collaboration, and license agreement with pharmaceutical [...]

Published
2022

22. BeiGene and Novartis Expand Collaboration to Develop, Commercialize, and Market BeiGene's TIGIT Inhibitor In China's broad markets, Novartis has five oncology medicines

Subjects
Novartis Pharma AG -- Licensing agreements, Antineoplastic agents -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Antimitotic agents -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

BASEL: BeiGene, Ltd., a global science-driven biotechnology company, today announced an option, collaboration and license agreement with Novartis Pharma AG to develop, manufacture and commercialize BeiGene's investigational TIGIT inhibitor ociperlimab [...]

Published
2021

23. BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene's TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets

Subjects
Novartis Pharma AG -- Licensing agreements, Antineoplastic agents -- Licensing agreements, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Antimitotic agents -- Licensing agreements, Company licensing agreement, Business, Business, international
Abstract

Strategic collaboration expected to advance clinical development of ociperlimab in combination with tislelizumab, including initiation and funding by Novartis of additional studies BeiGene expands commercial portfolio in China broad markets [...]

Published
2021

24. Precision BioSciences Forges In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease

Subjects
Novartis Pharma AG -- Licensing agreements, Sickle cell anemia, Genomics, Genes, Biotechnology industry -- Licensing agreements, Industrial research, Pharmaceutical industry -- Licensing agreements, Research and development, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-June 23, 2022-Precision BioSciences Forges In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease (C)2022 M2 COMMUNICATIONS - US-based clinical [...]

Published
2022

25. Codexis Announces Completion of CodeEvolver License Technology Transfer with Global Pharmaceutical Leader

Subjects
Novartis Pharma AG -- Licensing agreements, Codexis Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biological products -- Licensing agreements, Enzymes -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Redwood City, California: Codexis, Inc. has issued the following press release: Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the completion of [...]

Published
2021

26. Codexis Announces Completion of CodeEvolver License Technology Transfer with Global Pharmaceutical Leader

Subjects
United States. Securities and Exchange Commission, Novartis Pharma AG -- Licensing agreements, Codexis Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biological products -- Licensing agreements, Enzymes -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international, Law
Abstract

(GlobeNewswire) - Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the completion of the CodeEvolver platform technology transfer with Novartis Pharma AG [...]

Published
2021

27. Codexis Announces Completion of CodeEvolver(R) License Technology Transfer with Global Pharmaceutical Leader

Subjects
United States. Securities and Exchange Commission, Novartis Pharma AG -- Licensing agreements, Codexis Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biological products -- Licensing agreements, Enzymes -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

REDWOOD CITY, Jul 14, 2021 (GLOBE NEWSWIRE via COMTEX) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the completion of the [...]

Published
2021

28. NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex (Mazindol)

Subjects
Novartis Pharma AG -- Licensing agreements, Nervous system diseases, Mazindol -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international, Law, Sanorex (Medication) -- Licensing agreements
Abstract

NLS Pharma Ltd. (Nasdaq: NLSP, NLSPW) ('NLS' or the 'Company'), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex [...]

Published
2021

29. NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex (Mazindol)

Subjects
Novartis Pharma AG -- Licensing agreements, Nervous system diseases, Mazindol -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary, Sanorex (Medication) -- Licensing agreements
Abstract

Agreement provides exclusive rights to all available data included in the original new drug application ('NDA') for mazindol in the U.S. STANS, Switzerland, March 12, 2021 /PRNewswire/ -- NLS Pharmaceutics [...]

Published
2021

30. BeiGene Announced Closing of Collaboration with Novartis

Subjects
Novartis Pharma AG -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

CAMBRIDGE: BeiGene announced the closing of the collaboration and license agreement with Novartis Pharma AG, previously announced on January 11, 2021, to develop, manufacture, and commercialize BeiGene's anti-PD-1 antibody tislelizumab [...]

Published
2021

31. BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene's TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets

Subjects
Novartis Pharma AG -- Licensing agreements, Antineoplastic agents -- Licensing agreements, Drugs -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Antimitotic agents -- Licensing agreements, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-December 20, 2021-BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene's TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets (C)2021 M2 COMMUNICATIONS - Chinese [...]

Published
2021

32. CHMP adopts positive opinion

Subjects
Novartis Pharma AG -- Licensing agreements, Genmab A/S -- Licensing agreements, Ofatumumab -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Copenhagen: Genmab A/S said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion. This firm has announced that [...]

Published
2021

33. Mintz Advises BeiGene in Strategic Collaboration and Licensing Agreement with Novartis to Develop, Manufacture, and Commercialize Cancer Treatment, Tislelizumab

Subjects
Novartis Pharma AG -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Boston, Massachusetts: Mintz has issued the following press release: Mintz advised biotechnology company BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) in its recently announced collaboration and license agreement with pharmaceutical company [...]

Published
2021

34. BeiGene, Ltd.: INSIDE INFORMATION COLLABORATION WITH NOVARTIS TO DEVELOP AND COMMERCIALIZE ANTI-PD-1 ANTIBODY TISLELIZUMAB (Stock Code: 06160)

Subjects
Novartis Pharma AG -- Licensing agreements, Stock Exchange of Hong Kong Ltd. -- Licensing agreements, Viral antibodies, Antibodies, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Hong Kong: BeiGene, Ltd. has issued the following announcement: This announcement is issued pursuant to Rule 13.09 of the Rules Governing the Listing of the Securities on The Stock Exchange [...]

Published
2021

35. Novartis inks pact with Spark Therapeutics to develop, register & commercialize gene therapy voretigene neparvovec outside US

Subjects
Novartis Pharma AG -- Licensing agreements, Gene therapy, Genes, Pharmaceutical industry -- Licensing agreements, Drug approval, Company licensing agreement, Pharmaceuticals and cosmetics industries, Luxturna (Medication)
Abstract

Novartis announced a licensing agreement with Spark Therapeutics covering development, registration and commercialization rights to voretigene neparvovec in markets outside the US. Voretigene neparvovec, known as Luxturna (voretigene neparvovec-rzyl) in [...]

Published
2018

36. Intec Pharma enters Feasibility and Option agreement with Novartis

Subjects
Novartis Pharma AG -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

Intec Pharma (NTEC) announced it has entered into a Feasibility and Option agreement with Novartis Pharmaceuticals (NVS) to explore using the Accordion Pill platform for a proprietary Novartis compound. The [...]

Published
2018

37. Codexis Achieves Technology Transfer Milestone with Global Pharmaceutical Leader

Subjects
Novartis Pharma AG -- Licensing agreements, Codexis Inc. -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Biological products industry -- Licensing agreements, Technology, Novels, Company licensing agreement, Business, international, Law
Abstract

(GlobeNewswire) - Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces achievement of the Wave 2 milestone associated with the CodeEvolver platform technology transfer and license [...]

Published
2020

38. Codexis Achieves Technology Transfer Milestone with Global Pharmaceutical Leader

Subjects
Novartis Pharma AG -- Licensing agreements, Codexis Inc. -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Biological products industry -- Licensing agreements, Technology, Novels, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

REDWOOD CITY, May 06, 2020 (GLOBE NEWSWIRE via COMTEX) -- Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces achievement of the Wave 2 milestone associated [...]

Published
2020

39. NLS Pharmaceutics signs License Agreement with Novartis Pharma AG

Subjects
United States. Food and Drug Administration, Novartis Pharma AG -- Licensing agreements, Mazindol -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Chemistry, Sanorex (Medication) -- Licensing agreements
Abstract

M2 PHARMA-March 15, 2021-NLS Pharmaceutics signs License Agreement with Novartis Pharma AG (C)2021 M2 COMMUNICATIONS NLS Pharmaceutics Ltd (Nasdaq: NLSP, NLSPW), a Swiss clinical-stage pharmaceutical company, has signed a License [...]

Published
2021

40. NLS Pharmaceutics signs License Agreement with Novartis Pharma AG

Subjects
United States. Food and Drug Administration, Novartis Pharma AG -- Licensing agreements, Mazindol -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, Sanorex (Medication) -- Licensing agreements
Abstract

M2 EQUITYBITES-March 15, 2021-NLS Pharmaceutics signs License Agreement with Novartis Pharma AG (C)2021 M2 COMMUNICATIONS http://www.m2.com NLS Pharmaceutics Ltd (Nasdaq: NLSP, NLSPW), a Swiss clinical-stage pharmaceutical company, has signed a [...]

Published
2021

41. NLS Pharmaceutics signs License Agreement with Novartis Pharma AG

Subjects
United States. Food and Drug Administration, Novartis Pharma AG -- Licensing agreements, Mazindol -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, Sanorex (Medication) -- Licensing agreements
Abstract

M2 EQUITYBITES-March 15, 2021-NLS Pharmaceutics signs License Agreement with Novartis Pharma AG (C)2021 M2 COMMUNICATIONS http://www.m2.com NLS Pharmaceutics Ltd (Nasdaq: NLSP, NLSPW), a Swiss clinical-stage pharmaceutical company, has signed a [...]

Published
2021

42. NLS Pharmaceutics signs License Agreement with Novartis Pharma AG

Subjects
United States. Food and Drug Administration, Novartis Pharma AG -- Licensing agreements, Mazindol -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Chemistry, Sanorex (Medication) -- Licensing agreements
Abstract

M2 PHARMA-March 15, 2021-NLS Pharmaceutics signs License Agreement with Novartis Pharma AG (C)2021 M2 COMMUNICATIONS NLS Pharmaceutics Ltd (Nasdaq: NLSP, NLSPW), a Swiss clinical-stage pharmaceutical company, has signed a License [...]

Published
2021

43. BeiGene Forges Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan

Subjects
Novartis Pharma AG -- Licensing agreements, Viral antibodies, Antibodies, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-February 26, 2021-BeiGene Forges Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan (C)2021 M2 COMMUNICATIONS - China-based commercial-stage biotechnology company BeiGene, [...]

Published
2021

44. BeiGene Collaborates with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab

Subjects
Novartis Pharma AG -- Licensing agreements, Viral antibodies, Antibodies, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-January 12, 2021-BeiGene Collaborates with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab (C)2021 M2 COMMUNICATIONS - Chinese biotechnology company BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160), a commercial-stage biotechnology [...]

Published
2021

45. Premark Pharma Licenses Worldwide Rights to PMP2207 for Ophthalmic Indications and Targets a First Regulatory Approval for Blepharitis

Subjects
Novartis Pharma AG -- Licensing agreements, Ophthalmic agents -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Blepharitis, Anti-inflammatory agents, Real estate, Novels, Company licensing agreement, General interest, News, opinion and commentary
Abstract

BASEL: Pacific Sotheby's International Realty has issued the following press release: Premark Pharma announced today the completion of a licensing deal with Novartis Pharma AG, granting Premark exclusive worldwide rights [...]

Published
2019

46. MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner

Subjects
Novartis Pharma AG -- Licensing agreements, MorphoSys AG -- Licensing agreements, Biotechnology industries -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Biological products industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Mechelen, Belgium and Planegg/Munich, Germany; 12 September 2018; 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; [...]

Published
2018

47. Ad hoc: MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Novartis and MorphoSys Increases its Financial Guidance for 2018

Subjects
Novartis Pharma AG -- Licensing agreements, MorphoSys AG -- Licensing agreements, Biotechnology industries -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Antitrust law, Biological products industry -- Licensing agreements, Antitrust issue, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Germany: MorphoSys AG has issued the following press release: Ad hoc: MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Novartis and MorphoSys Increases its Financial Guidance for 2018 [...]

Published
2018

48. MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

Subjects
Novartis Pharma AG -- Licensing agreements, MorphoSys AG -- Licensing agreements, Monoclonal antibodies, Biotechnology industries -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Biological products industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) announced today that they have entered into a worldwide, exclusive agreement with Novartis [...]

Published
2018

49. MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

Subjects
Novartis Pharma AG -- Licensing agreements, MorphoSys AG -- Licensing agreements, Monoclonal antibodies, Atopic dermatitis, Biotechnology industries -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Biological products industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Belgium: Galapagos NV has issued the following press release: Exclusive global license agreement with Novartis on MOR106 MOR106, a monoclonal antibody directed against IL-17C, will be developed further in atopic [...]

Published
2018

50. MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

Subjects
Novartis Pharma AG -- Licensing agreements, MorphoSys AG -- Licensing agreements, Monoclonal antibodies, Atopic dermatitis, Biotechnology industries -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Biological products industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- - Exclusive global license agreement with Novartis on MOR106 - MOR106, a monoclonal antibody directed against IL-17C, will be developed further in atopic dermatitis (AtD) [...]

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results